Project Grant RC2TR006121
- The National Center for Advancing Translational Sciences awarded a $10.805 million Cooperative Agreement to the University of Pennsylvania on July 1, 2026, under the National Center for Advancing Translational Sciences program (CFDA 93.350). The Penn-CHOP Clinical and Translational Science Award (CTSA) Hub will advance clinical and translational science through four integrated aims: developing and disseminating novel approaches to translational therapeutics; applying data science resources and...
- The National Center for Advancing Translational Sciences awarded the University of Pennsylvania $1.62 million on August 1, 2026, under the NCATS program (CFDA 93.350) to operate a mentored research career development program in clinical and translational science. The University of Pennsylvania will identify, recruit, train, and retain nine early-career scientists across varied educational backgrounds and professional experiences, guiding them toward scientific independence and leadership in...
- The National Institutes of Health National Center for Advancing Translational Sciences awarded the University of Pennsylvania $532,701 on July 6, 2026, under the National Center for Advancing Translational Sciences program (CFDA 93.350) to support a postdoctoral training program in clinical and translational science. The award funds the CTSA Postdoctoral T32 at Penn, which trains clinical and translational science investigators to move scientific discoveries from the laboratory into clinical...
- The National Center for Advancing Translational Sciences awarded the University of Pennsylvania $553,631 on July 6, 2026, under the CTSA Predoctoral T32 program (CFDA 93.350) to support predoctoral trainee development in clinical and translational science. The award funds a predoctoral training program that will support 10 trainees at any given time, recruited from PhD, MD, DMD, and VMD doctoral programs, with individual appointments lasting 1–3 years depending on career stage. The training plan...
- The National Center for Advancing Translational Sciences awarded a cooperative agreement totaling $7.892 million to Pennsylvania State University (operating as Penn State Milton S. Hershey Medical Center) on August 6, 2026, under CFDA 93.350. The award funds the Penn State Clinical and Translational Science Institute (CTSI) to advance clinical and translational science through investigator-centered research infrastructure, development and dissemination of innovations, expansion of Pennsylvania's...
- The National Center for Advancing Translational Sciences awarded Pennsylvania State University (operating as Penn State Milton S. Hershey Medical Center) $725,350 on August 13, 2026, under the NCATS K12 Program (CFDA 93.350) to support early-career faculty development in translational science. The award funds a structured 2–3 year intensive career development and research training program for 3 cohorts of early-career faculty scholars (3 scholars per cohort), organized around three pillars:...
- Federal Project Grant Award Summary The University of Pennsylvania received a $1,204,698 Project Grant from the National Center for Advancing Translational Sciences (NCATS, CFDA 93.350) awarded July 1, 2025, through June 30, 2027, to advance trial readiness for LCAT deficiency, an ultra-rare autosomal recessive genetic condition. The project focuses on identifying and validating biomarkers to support clinical development of emerging therapeutics, including gene therapy approaches for this...
- The National Institute of Child Health and Human Development awarded the University of Pittsburgh $248,858 on July 1, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to develop and test network interventions that increase adoption of evidence-based obesity prevention strategies among community coalitions serving low-income populations. The research addresses the 23–33 percent higher obesity prevalence among children from socioeconomically...
- The National Institute of Child Health and Human Development awarded The Trustees of The University of Pennsylvania $683,352 on August 1, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to develop novel causal inference and machine learning methods and user-friendly software designed to reconcile conflicting results from randomized controlled trials. The project addresses the challenge that large, well-designed RCTs with near-identical protocols...
- The National Center for Advancing Translational Sciences awarded The Pennsylvania State University $321,700 on June 1, 2026, under CFDA 93.350 to develop and test the WEAR-IT smartphone research platform for reducing rural participation barriers in translational research and clinical trials. The WEAR-IT platform operates on an edge-of-cloud computing model, processing data on-device to ensure fast, responsive performance even when internet connectivity is limited, and uploading data to cloud...
The National Center for Advancing Translational Sciences awarded the University of Pennsylvania $3.312 million on August 10, 2026, under the National Center for Advancing Translational Sciences program (CFDA 93.350) to develop and test infrastructure for parent-child behavioral interventions addressing obesity in families. The project, titled "Research Redesign to Reduce Chronic Conditions in Families," combines the adult-focused resources of the University of Pennsylvania with the pediatric expertise of the Children's Hospital of Philadelphia and the collaborative capacity of the CTSA Hub to advance a novel infrastructure for integrated translational research. The work centers on BE ACTIVE+, an intervention program that adapts behavioral economic strategies to increase physical activity and improve dietary quality in families through gamified incentives, wearable devices, social accountability, and provision of high-quality supplemental nutrition. The recipient will pursue three specific aims: developing and testing foundational infrastructure using linked electronic health records, practice-based research networks, and a gamified technology platform; refining the infrastructure through human-centered design and pilot testing; and conducting a prospective study testing BE ACTIVE+ in adult-child dyads with obesity. Performance is located in Philadelphia, Pennsylvania, with a period of performance from August 10, 2026, through May 31, 2030.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $3.3m | 8/3/26 |